Direct-to-consumer advertising and shared liability for pharmaceutical manufacturers

JAMA

Volumn 289, Issue 4, 2003, Pages 477-481

  Mello, Michelle M ^a   Rosenthal, Meredith ^a   Neumann, Peter J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; CONSUMER; DOCTOR PATIENT RELATION; DRUG INDUSTRY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; LEGAL ASPECT; LEGAL LIABILITY; NOTE; POLICY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0037460199     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.4.477     Document Type: Note

References (51)

1. Food and Drug Administration. Draft Guidance to Industry: Consumer-Directed Broadcast Advertisements. Rockville, Md: National Press Office; 1997.
2. Newshour with Jim Lehrer, Henry J. Kaiser Family Foundation, and Harvard School of Public Health. National Survey on Prescription Drugs. Menlo Park, Calif: Henry J. Kaiser Family Foundation; 2000.
3. Crawford LM Jr. Commercial speech and public health: request for comment [From the Food and Drug Administration]. JAMA. 2002;288:36.
4. Schwartz TM. Consumer-directed prescription drug advertising and the learned intermediary rule. Food Drug Cosmetics Law J. 1991;46:829-848.
5. Plant NK. The learned intermediary doctrine: some new medicine for an old ailment. Iowa Law Rev. 1996;81:1007-1078.
6. Perez v Wyeth Laboratories Inc, 734 A2d 1245 (NJ 1999).
7. Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising Has Limitations. Washington, DC: General Accounting Office; 2002.
8. Hammack L. Conn attorney general blasts OxyContin. Roanoke Times & World News. August 7, 2001:B1.
9. Elliott VS. Patient-focused drug campaigns may exploit data, invade privacy. American Medical News. July 29, 2002. Available at: http://www.ama-assn.org /sci-pubs/amnews/pick_O2/hll10729.htm. Accessed August 28, 2002.
10. Lota L. Judge bans some anti-depressant ads. Associated Press. August 20, 2002. Available at: http: //www.depressionisachoice.com/essays/paxil.htm. Accessed August 28, 2002.
11. Gemperli MP. Rethinking the role of the learned intermediary: the effect of direct-to-consumer advertising on litigation [MSJAMA]. JAMA. 2000;284:2241.
12. Restatement (Third) of Torts: Products Liability. Philadelphia, Pa: American Law Institute; 1997:4, 6d.
13. Dreier WA. Direct-to-consumer advertising liability: an empty gift to plaintiffs. Seton Hall Law Rev. 2000;30:806-826.
14. Vitanza v Upjohn, 778 A2d 829, 846-847 (Conn 2001).
15. Karns JE. Direct advertising of prescription drugs: the duty to warn and the learned intermediary rule. DePaul J Health Care Law. 2000;3:273-291.
16. Procedures for Submission of a Supplement to an Approved Application, 21 CFR §314.17(b)(3)(1) (2001).
17. Manning RL. Products liability and prescription drug prices in Canada and the United States. J Law Econ. 1997;40:203-243.
18. Murphy J, Chang H, Montgomery JE, et al. The quality of physician-patient relationships: patients' experiences 1996-1999. J Fam Pract. 2001;50:123-129.
19. Brodie M, Flournoy RE, Altman DE, et al. Health information, the Internet, and the digital divide. Health Aff (Millwood). 2000;19:255-265.
20. Henry J. Kaiser Family Foundation. Understanding the Effects of Direct-to-Consumer Prescription Drug Advertising. Menlo Park, Calif: Henry J. Kaiser Family Foundation; 2001.
21. Prevention Magazine. International Survey on Wellness and Consumer Reaction to DTC Advertising of Prescription Drugs, Volume 1: 2000/2001. Emmaus, Pa: Rodale; 2001.
22. Lipsky MS, Taylor CA. The opinions and experiences of family physicians regarding direct to consumer advertising. J Fam Pract. 1997;45:495-499.
23. Mintzes B, Barer ML, Kravitz RL, et al. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ. 2002;324:278-279.
24. Spurgeon D. Doctors feel pressurised by prescription direct to consumer advertising. BMJ. 1999;319:1321.
25. Bell RA, Wilkes MS, Kravitz RL. Advertisement-induced prescription drug requests: patients' anticipated reactions to a physician who refuses. J Fam Pract. 1999; 48:446-452.
26. Noah L. Advertising prescription drugs to consumers: assessing the regulatory and liability issues. Georgia Law Rev. 1997;32:141-180.
27. Kravitz RL. Direct-to-consumer advertising of prescription drugs: implications for the patient-physician relationship. JAMA. 2000;284:2244.
28. Allen v GD Searle & Co, 708 F Supp 1142 (D Ore 1989).
29. Ausness RC. Will more aggressive marketing practices lead to greater tort liability for prescription drug manufacturers? Wake Forest Law Rev. 2002;37:97-139.
30. Mechanic D, McAlpine DD, Rosenthal M. Are patients' office visits with physicians getting shorter? N Engl J Med. 2001;344:198-204.
31. Balkrishnan R, Hall MA, Mehrabi D, et al. Capitation payment, length of visit, and preventive services: evidence from a national sample of outpatient physicians. Am J Manage Care. 2002;8:332-340.
32. Morris LA, Tabak ER, Gondek K. Counseling patients about prescribed medication: 12-year trends. Med Care. 1997;35:996-1007.
33. Davis TC, Fredrickson DD, Bocchini C, et al. Improving vaccine risk/benefit communication with an immunization package: a pilot study. Ambul Pediatr. 2002; 2:193-200.
34. Kalet A, Roberts JC, Fletcher R. How do physicians talk with their patients about risks? J Gen Intern Med. 1994;9:402-404.
35. Braddock CH III, Fihn SD, Levinson W, et al. How doctors and patients discuss routine clinical decisions: informed decision making in the outpatient setting J Gen Intern Med. 1997;12:339-345.
36. Braddock CH III, Edwards KA, Hasenberg NM, et al. Informed decision making in outpatient practice: time to get back to basics. JAMA. 1999;282:2313-2320.
37. Sharp LA, Malpractice: physician's liability for injury or death resulting from side effects of drugs intentionally administered to or prescribed for patient. Am Law Rep. 1997;47:433.
38. Morris LA, et al. Miscomprehension rates for prescription drug advertisements. Curr Issues Res Advertis. 1986;9:93-117.
39. Schommer JC, Doucette WR, Mehta BH. Rote learning after exposure to a direct-to-consumer television advertisement for a prescription drug. Clin Ther. 1998; 20:617-632.
40. Bell RA, Kravitz RL, Wilkes MS. Direct-to-consumer advertising and the public. J Gen Intern Med. 1999;14:651-657.
41. Cohen EP. Direct-to-the-public advertisement of prescription drugs. N Engl J Med. 1988;318:373-376.
42. Roth MS. Patterns in direct-to-consumer prescription drug print advertising and their policy implications. J Public Policy Marketing. 1996;15:63-75.
43. Wilkes MS, Bell RA, Kravitz RL. Direct-to-consumer prescription drug advertising: trends, impact, and implications, Health Aff (Millwood). 2000;19:110-128.
44. Carmichael v Reitz, 95 Cal Rptr 381 (Ct App 1971).
45. Holmer AF. Direct-to-consumer advertising: strengthening our health care system. N Engl J Med. 2002;346:526-528.
46. Thompson v Western States Medical Center, 122 SCt 1497 (2002).
47. Calabresi G. The Costs of Accidents: A Legal and Economic Analysis. New Haven, Conn: Yale University Press; 1970.
48. Schwartz GT. Reality in the economic analysis of tort law: does tort law really deter? UCLA Law Rev. 1994;42:377-444.
49. Mello MM, Brennan TA. Deterrence of medical errors: theory and evidence for malpractice reform. Tex Law Rev. 2002;80:1595-1637.
50. Rosok MJ. Direct-to-consumer advertising of prescription drugs: after a decade of speculation, courts consider another exception to the learned intermediary rule. Seattle Univ Law Rev. 2000;24:629-661.
51. Huber P. Safety and the second best: the hazards of public risk management in the courts. Columbia Law Rev. 1985;85:277-337.